<DOC>
	<DOC>NCT02320045</DOC>
	<brief_summary>A Phase 1 study to evaluate the pharmacokinetics of ITCA 650 in subjects with mild and moderate renal impairment compared to the pharmacokinetics of subjects with normal renal function</brief_summary>
	<brief_title>Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Body mass index between 22 and 40 kg/m² Subjects meeting predefined estimated glomerular filtration rate criteria and creatinine clearance rate Normal (≥90 mL/min/1.73 m2) Mild (6089 mL/min/1.73 m2) Moderate (4559 mL/min/1.73 m2) Moderate (&gt;3044 mL/min/1.73 m2) History of acute metabolic complications Uncontrolled Hypertension History of Hypersensitivity to Exenatide Cardiovascular Disease History of Acute or chronic pancreatitis Personal or family history of Multiple endocrine neoplasia type 2 History of Medullary thyroid cancer Severe renal failure, End stage renal disease or dialysis</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>